GNX 5086

Drug Profile

GNX 5086

Alternative Names: GNX-5086

Latest Information Update: 29 Aug 2013

Price : $50

At a glance

  • Originator Congenia
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myocardial reperfusion injury

Most Recent Events

  • 15 Aug 2013 Phase-I clinical trials in Myocardial reperfusion injury (in volunteers) in Netherlands (IV)
  • 24 Jul 2013 Regulatory authorities in the Netherlands approve CTA for GNX-5086 in Myocardial reperfusion injury
  • 04 Jul 2013 Congenia files a CTA with the regulatory authorities in the Netherlands for Myocardial reperfusion injury
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top